Vaccine adopting subcellular structure and preparation method of vaccine

Abstract

The invention discloses a vaccine adopting the subcellular structure and a preparation method of the vaccine. On the basis that short-lived protein in tumor cells is induced by bortezomib and ammonium chloride and a defective ribosome product is used as antigen protein, the vaccine adopting the subcellular structure enters autophagic vacuoles adopting the double-membrane structure through an autophagy pathway, the autophagic vacuoles coating tumor antigens are collected and then modified by HSP70 immune activation peptide fragments, modified autophagic vacuoles are the vaccine adopting the subcellular structure, and the vaccine is delivered through lymph glands, can effectively induce cross presentation of a body immune system and activate CD4+ and CD8+ T lymph cells and CTL cells, and has the better tumor killing effect.

Description

technical field [0001] The invention belongs to the field of vaccines, and in particular relates to a subcellular structure vaccine and a preparation method thereof. Background technique [0002] Tumor biological therapy is developing rapidly. At present, a large number of vaccines have entered the clinical trial stage. Tumor vaccines include tumor cell vaccines, tumor-associated antigen vaccines, nucleic acid vaccines, and related active immune cell vaccines. However, due to factors such as immune escape, protein antigens or antigenic peptides, etc. It is difficult for a vaccine with a single antigenic component to show significant clinical efficacy. [0003] The tumor antigen components derived from whole tumor cells are diverse, but due to the perfect self-protection mechanism of tumor cells, only the long-lived protein antigens that are easy to induce immune tolerance can be retained, and tolerance to these antigens is easily formed in the autoimmune system. It lacks co...

AI Technical Summary

Problems solved by technology

[0002] Tumor biological therapy is developing rapidly. At present, a large number of vaccines have entered the clinical trial stage. Tumor vaccines include tumor cell vaccines, tumor-associated antigen vaccines, nucleic acid vaccines, and related active immune cell vaccines. However, due to factors such as immune escape, protein antigens or antigenic peptides, etc. Vaccines with a single antigenic component are difficult to show significant clinical efficacy

[0003] The tumor antigen components derived from whole tumor cells are diverse, but due to the perfect self-protection mechanism of tumor cells, only the long-lived protein antigens that are easy to induce immune tolerance can be retained, and tolerance to these antigens is easily formed in the autoimmune system. Lack of short-lived proteins and other components that current studies believe can induce T cell responses

The subcellular structure vaccines derived from autophagosomes in the prior art have shown certain tumor suppression effects in animal experiments, but in clinical applications, due to differences in human immune mechanisms and individual disease, the clinical effects of autophagosome vaccines still remain. room for improvement

Images